7 December 2021 Please note that the SAHPRA office will be closed for the festive season from 12h00 on Friday the 24th of December 2021 and will re-open on Monday the 3rd of January 2022. In case of emergencies kindly contact the respective Senior Managers. Medical Devices and...
26 November 2021 Embargo: Immediate release SAHPRA has received an application for the Pfizer Comirnaty Booster/3rddose vaccine on 17 November 2021. This is for the homologous booster regimen, not a mix-and-match approach. SAHPRA will now commence with the assessment of data for the safety and efficacy of the third...
22 November 2021 In June 2021, SAHPRA communicated that South Africa would not accept any product or ingredients made at the Emergent BioSolutions facility in Baltimore, Maryland until the Inspectorate conducted an onsite/remote inspection. This facility manufactures a drug substance used in some doses of the...
18 October 2021 SAHPRA has been engaged in a rolling review of the data for the Sputnik V COVID-19 vaccine since the initial application was submitted on 23 February 2021. This vaccine was developed by the Gamaleya Research Institute of Epidemiology and Microbiology in the Russian...
30 September 2021 Attention all stakeholders Post Importation Testing Exemptions (PITE) granted due to COVID-19 pandemic Post importation testing exemption approvals granted since March 2020 due to the Covid-19 pandemic, are extended to March 2022 without further need of an application thereof. Post-Importation Testing Exemptions (PITE) expiring prior to...
10 September 2021 The South African Health Products Authority (SAHPRA) has approved the use of the Pfizer COMIRNATY Vaccine in terms of Section 21 of the Medicines and Related Substance Act 101 of 1965 (The Medicines Act) to include individuals twelve years (12) years and older....
3 September 2021 The South African Health Products Regulatory Authority (SAHPRA) is aligned with the United States Food and Drug Administration (USFDA) call to not use Ivermectin for the treatment of COVID-19. This stance is reflected in the SAHPRA statement, dated 28 January 2021, outlining SAHPRA’s views on Ivermectin and the Controlled Compassionate Use Programme. SAHPRA...
30 July 2021 The South African Health Products Regulatory Authority (SAHPRA) is an independent, science-based entity that follows strict guidelines and processes when approving health products. SAHPRA concerns itself, like other regulators across the world, with safety, quality and efficacy of health products. These essential requirements...
20 August 2021 The South African Health Products Regulatory Authority (SAHPRA) has a mandate to oversee the safety, efficacy and quality of all medicines registered in South Africa, including vaccines. The National Department of Health (NDoH) Expanded Programme on Immunisation (EPI) is responsible for the COVID-19...
19 July 2021 As South Africa’s statutory health regulatory bodies, the South African Health Products Regulatory Authority (SAHPRA), Health Professions Council of South Africa (HPCSA), Office of Health Standards Compliance (OHSC), South African Nursing Council (SANC) and South African Pharmacy Council (SAPC) together with the National...
